trial

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

NCTId NCT02228395
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 12 (actual)
Sponsored by Biogen
Primary completion 2014-11-13
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2014-09-22
Primary completion
2014-11-13
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-04958242
Indications
Healthy

Sponsors

BiogenLead Sponsor

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2014-11-13
Status
COMPLETED
relationships
The graph out of here
drug
PF-04958242
drug
lead_sponsor
Biogen
company
indication
Healthy
indication